ALESSE Drug Patent Profile

When do Alesse patents expire, and what generic alternatives are available?

Alesse is a drug marketed by Cadence Health and is included in one NDA.

The generic ingredient in ALESSE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for ALESSE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ALESSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cadence Health	ALESSE	ethinyl estradiol; levonorgestrel	TABLET;ORAL-21	020683-001	Mar 27, 1997		DISCN	Yes	No
Cadence Health	ALESSE	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	020683-002	Mar 27, 1997		DISCN	Yes	No

Alesse: Market Landscape and Investment Outlook

Last updated: February 19, 2026

Alesse, a combined oral contraceptive containing ethinyl estradiol and levonorgestrel, faces a mature and competitive market. Its patent expiration in 2009 has led to genericization, significantly impacting its pricing power and market share. The primary investment thesis for Alesse revolves around the performance of its generic versions and the broader market dynamics of the oral contraceptive segment.

What is the Current Market Position of Alesse?

Alesse, originally marketed by Wyeth (now part of Pfizer), is a well-established oral contraceptive. Its active ingredients, ethinyl estradiol and levonorgestrel, are common in many generic formulations. The branded product has experienced a substantial decline in market share following the expiration of its primary patents.

• Branded Market Share Decline: Post-patent expiration, the market share for branded Alesse has diminished considerably. Generic manufacturers have entered the market, offering lower-cost alternatives.
• Generic Dominance: The oral contraceptive market is largely dominated by generic products. Pharmaceutical companies that have successfully manufactured and distributed generic versions of Alesse have captured significant market volume.
• Pricing Pressure: The presence of multiple generic competitors has resulted in intense pricing pressure, making it challenging for any single manufacturer to command premium pricing.

What are the Key Fundamentals Driving the Alesse Market?

The fundamentals of the Alesse market are tied to the demand for oral contraceptives and the competitive landscape.

• Demand Drivers: Demand for oral contraceptives remains strong due to their efficacy in preventing unintended pregnancies and their use in managing gynecological conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Demographic trends, including reproductive-age populations and family planning choices, influence overall demand.
• Competitive Landscape: The market is fragmented with numerous generic manufacturers. Key players include Teva Pharmaceuticals, Mylan (now Viatris), and Actavis (now part of AbbVie). Competition is primarily based on price and supply chain reliability.
• Regulatory Environment: Regulatory bodies like the U.S. Food and Drug Administration (FDA) oversee the approval and manufacturing of generic drugs. Compliance with Good Manufacturing Practices (GMP) is crucial for market participation.
• Manufacturing Costs: The cost of manufacturing active pharmaceutical ingredients (APIs) and finished dosage forms is a significant factor. Economies of scale and efficient supply chains are critical for profitability in the generic space.

What is the Patent Status of Alesse?

The original patents protecting branded Alesse have expired. This has opened the door for widespread generic competition.

• Exipration Dates: Key patents for Alesse expired around 2009. This allowed generic manufacturers to launch their versions of the drug.
• Exclusivity Periods: While the primary patents have expired, there could be minor secondary patents or formulation patents that might have offered limited residual exclusivity, but these typically do not prevent broad generic entry.
• Generic Entry: The expiration of patents directly led to the introduction of multiple generic equivalents, fragmenting the market and driving down prices.

How Does the Generic Market for Alesse Perform?

The performance of Alesse is now predominantly determined by the success of its generic versions.

• Market Volume: Generic Alesse formulations collectively hold a substantial volume share of the oral contraceptive market. The total market size for oral contraceptives, which includes Alesse and its competitors, provides a baseline for generic performance.
• Pricing Strategy: Generic manufacturers compete on price, often engaging in bidding wars for formulary placement with insurance providers and pharmacy benefit managers (PBMs).
• Supply Chain Reliability: Consistent and reliable supply is a critical differentiator for generic drug manufacturers. Stock-outs can lead to lost market share.
• Manufacturing Capacity: Companies with robust manufacturing capabilities and efficient production processes are better positioned to compete.

What are the Risks and Opportunities for Investors in the Alesse Market?

Investing in the Alesse market, primarily through generic manufacturers, presents specific risks and opportunities.

Risks

• Intense Competition: The high degree of competition among generic manufacturers can lead to declining profit margins.
• Price Erosion: Continuous price reductions are a characteristic of the generic oral contraceptive market, impacting revenue.
• Regulatory Hurdles: Any manufacturing issues or quality control failures can lead to product recalls, regulatory sanctions, and reputational damage.
• Therapeutic Class Substitutes: While Alesse is an established option, new hormonal contraceptives with different formulations or delivery methods can emerge, potentially shifting market preferences.
• Market Access Issues: Changes in payer policies or formulary restrictions can affect a generic product's accessibility and sales volume.

Opportunities

• Consistent Demand: Oral contraceptives remain a widely used class of drugs with sustained demand.
• Economies of Scale: Larger generic manufacturers can leverage economies of scale in production and procurement to achieve cost advantages.
• Portfolio Diversification: Companies with a broad portfolio of generic drugs, including other contraceptives, can mitigate risks associated with any single product.
• Emerging Markets: Expanding access to affordable healthcare in emerging markets can create new demand for generic contraceptives.
• Contract Manufacturing: Opportunities may exist for contract manufacturing organizations (CMOs) to produce generic Alesse for various pharmaceutical companies.

What is the Competitive Landscape for Oral Contraceptives?

Alesse competes within a broad and dynamic oral contraceptive market. Key competitors include other combined oral contraceptives and progestin-only pills.

• Key Branded Competitors (Historically): Ortho Tri-Cyclen, Lo Loestrin Fe, Yaz, NuvaRing, Nexplanon. Many of these also face or have faced generic competition.
• Generic Competitors: Numerous companies offer generic versions of ethinyl estradiol and levonorgestrel combination pills. Examples include formulations from Teva, Sun Pharma, and various others.
• Market Segmentation: The oral contraceptive market is segmented by hormone type (estrogen-progestin vs. progestin-only), dosage strength, and administration (pill, patch, ring). Alesse falls into the estrogen-progestin pill category.
• Product Differentiation: While Alesse is a mature product, newer oral contraceptives may offer advantages in terms of lower hormone doses, different progestin types (e.g., drospirenone), or improved side effect profiles, creating competitive pressure.

How has Regulatory Policy Impacted the Generic Alesse Market?

Regulatory policies significantly shape the generic drug market, including that for Alesse.

• Abbreviated New Drug Application (ANDA) Process: The FDA's ANDA process allows generic manufacturers to demonstrate bioequivalence to the reference listed drug (RLD), facilitating market entry post-patent expiration.
• Generic Drug User Fee Amendments (GDUFA): GDUFA legislation has aimed to accelerate the availability of safe and effective generic drugs by improving the FDA's review process and increasing transparency.
• Drug Shortage Provisions: Regulations addressing drug shortages can incentivize manufacturers to maintain adequate supply and can also lead to temporary approvals for alternative suppliers.
• Post-Market Surveillance: The FDA monitors generic drugs for safety and efficacy after they enter the market. Any adverse event reports or quality issues can lead to regulatory action.

What is the Outlook for Manufacturers Producing Generic Alesse?

The outlook for manufacturers producing generic Alesse is one of steady, albeit low-margin, volume-driven business.

• Volume Stability: The demand for oral contraceptives is relatively stable, providing a consistent revenue stream for established generic products.
• Margin Compression: Profit margins are expected to remain tight due to ongoing price competition. Companies must focus on operational efficiency and cost control.
• Strategic Importance: While Alesse may not be a high-growth product, it can be an important part of a generic manufacturer's portfolio, contributing to overall revenue and market presence.
• Acquisition and Consolidation: The generic pharmaceutical industry has seen significant consolidation. Larger players may acquire smaller companies with established generic portfolios, including Alesse.

Key Takeaways

• Branded Alesse has experienced market erosion due to patent expiration and subsequent genericization.
• The market for Alesse is now dominated by generic versions, characterized by intense price competition and volume-driven sales.
• Demand for oral contraceptives remains robust, providing a stable, though low-margin, market for generic Alesse.
• Key investment considerations include the manufacturing efficiency, supply chain reliability, and pricing strategies of generic producers.
• Regulatory compliance and effective market access are critical for sustained success in the generic Alesse segment.

Frequently Asked Questions

1. What is the primary therapeutic use of Alesse? Alesse is used as a combined oral contraceptive to prevent pregnancy. It can also be prescribed for managing conditions like acne, endometriosis, and polycystic ovary syndrome.

2. When did the patents for Alesse expire, allowing for generic versions? The primary patents for Alesse expired around 2009.

3. Who are the major generic manufacturers of Alesse? Major generic manufacturers include companies such as Teva Pharmaceuticals, Mylan (now Viatris), and Accord Healthcare, among others that produce bioequivalent formulations.

4. How does the pricing of generic Alesse compare to the original branded product? Generic Alesse is significantly less expensive than the original branded product, reflecting the competitive nature of the generic drug market and the absence of patent-protected premiums.

5. What factors contribute to profitability for companies manufacturing generic Alesse? Profitability is driven by economies of scale in manufacturing, efficient supply chain management, strong relationships with distributors and payers, and maintaining high-quality production standards to avoid costly recalls or regulatory issues.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Generic Drugs Program. Retrieved from [FDA Website] [2] Various pharmaceutical company investor reports and product information (confidential data not publicly attributable for specific market share analysis). [3] World Health Organization. (n.d.). Family Planning/Contraception. Retrieved from [WHO Website] [4] European Medicines Agency. (n.d.). Generic medicines. Retrieved from [EMA Website] [5] IQVIA. (n.d.). Pharmaceutical Market Data and Analytics. (Proprietary market data access required for specific market share figures).